AK-006

N/A

Report date: 2023/10/13 20:08:36

Base Information

Drug NameAK-006
Drug Alias NameAK006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsMast cells inhibitorsImmunomodulators +[4] 
TargetsSialic acid-binding Ig-like lectin 6
Therapy Area/IndicationsInflammationChronic Urticaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAllakos Inc
China Registration ClassN/A

Develop Information

Active CompaniesAllakos Inc
Inactive CompaniesN/A
Active IndicationsInflammationChronic Urticaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A